Kornimate/medical-research-clean huggingface dataset:
a study of brt-fc-83c for the treatment of atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of the study is to determine whether the topical application of brt-fc-83c is effective in the treatment of mild to moderate atopic dermatitis.

atopic dermatitis is a common skin disease. brt-fc-83c is a skin cream that does not contain corticosteroids or other anti-inflammatory components. it represents a novel class of skin barrier repair therapy for chronic dermatoses. the objective of this clinical study is to determine whether brt-fc-83c, applied twice a day to the affected area of the skin, ameliorates signs and symptoms of mild to moderate atopic dermatitis.

Eligibility criteria:
inclusion criteria: * clinically verified mild to moderate atopic dermatitis. atopy diagnosis based on clinical scores of 3-7.5 based on the rajka and langeland criteria * men or women ages 18-50 years * at least one mild to moderate atopic lesion involving no more than 20% body surface area (bsa) * active atopic dermatitis for at least 3 years * willingness to cooperate and participate by following study requirements * written informed consent exclusion criteria: * individuals with actively oozing atopic lesions * individuals who are smokers * individuals with insulin-dependent diabetes mellitus * individuals that are known to be pregnant, nursing, or planning to become pregnant within the next six months after enrollment * individuals currently participating in another clinical usage study that would interfere with this study

Keywords: efficacy
telerehabilitation on physical and mental health of the elderly in the covid-19 pandemic context

Conditions: Elderly Women

Summary: introduction: due to the covid-19 pandemic scenario, social distancing has become the main strategy to contain this pandemic, causing negative impacts on the physical and mental health of the elderly population. to promote the continuity of offering health services during isolation telerehabilitation was used. thus, it is important to investigate the effect of a physical exercise program and health education through telerehabilitation on physical and mental aspects in order to establish it as an alternative care for the elderly. objectives: to evaluate the effect of a program of physical exercises and health education by telerehabilitation on signs of sarcopenia, physical performance, hand grip strength and levels of anxiety, depression and sleep quality in elderly women. method: in this non-randomized clinical trial, considered a pilot study, eight elderly women (73,00±4,69 years old) will be submitted to 16 weeks of intervention through a program of physical exercise and health education using the google meet platform (synchronous online), frequency of 3 weekly sessions and duration of 50' (initial rest: 5'; warm-up: 15': resistance exercises: 20'; stretching exercises: 5'; relaxation and final rest: 5'). before and after the intervention period, the following tests will be applied: sarc-f, short physical performance battery, hand-grip dynamometry, geriatric anxiety inventory, geriatric depression scale and pittsburgh sleep quality index. to compare the two moments, the paired student's t-test or wilcoxon test (normality assessed by the shapiro-wilk test) will be used with p\<0.05.


Eligibility criteria:
inclusion criteria: * women aged 60 years or older; * able to perform all the proposed assessments; * not present cognitive impairment according to the assessment of mental status through the mini mental state examination; * participate in the supervised physical exercise program in person, prior to the beginning of the covid-19 pandemic. exclusion criteria: * had a frequency of participation in the program below 75%.

Keywords: health services for the aged telemonitoring exercise health education covid-19
rampart duo clinical (radical) post-market study

Conditions: Lumbar Degenerative Disc Disease

Summary: this exempt, minimal risk, prospective, post-market, registry, multi-center, institution review board (irb) approved observational clinical evaluation was conducted at 10 centers. a total of 197 patients were enrolled. the evaluation collected data in a real-world patient population and was a data collection initiative only. no patient treatments or care were performed as a component of the protocol. all patient care received was on-label and standard of care for lateral lumbar interbody fusions. the data collected in this evaluation is intended to contribute to the body of literature for lateral lumbar interbody fusions.

the purpose of this study was to collect data that reports on the clinical outcomes of patients that were treated with the spineology rampart duo device in a standard of care instrumented lateral lumbar interbody fusion procedure at one or two contiguous levels from l2-l5. data was collected prospectively at specified time points per protocol and included both objective and subjective measures. the study concluded when the final patient achieved their 12-month evaluation.

Eligibility criteria:
inclusion criteria: * a clinical decision has been made to treat the patient with the rampart duo interbody spacer prior to enrollment into this research evaluation. this decision is independent (made outside) of the decision to take part in the research. exclusion criteria: * previous interbody fusion or total disc replacement at the index level(s). * enrolled in a concurrent clinical investigation that may confound the findings of the present investigation.
safety and efficacy of human insulin inhalation powder in patients with type 1 diabetes mellitus.

Conditions: Diabetes Mellitus, Type 1

Summary: this is a research study of a study drug known as ly041001 or human insulin inhalation powder (hiip). hiip is a powder form of insulin made to be inhaled through the mouth and into the lungs using a special handheld device.


Eligibility criteria:
inclusion criteria: * you are at least 18 years old. * you have had type 1 diabetes for at least 2 years. * you are injecting insulin lispro (humalog), an insulin lispro mixture (humalog mixture), regular human insulin mixture (humulin mixture) before meals using a syringe or injection pen, not an insulin pump. * if you are female and could become pregnant, you test negative for pregnancy based on blood test at the beginning of the study, do not intend to become pregnant, and agree to use a form of birth control approved by the investigator during the study. * you have not smoked for at least 1 year, and you agree not to smoke or use smokeless tobacco during the study. exclusion criteria: * you have used an experimental drug during the last 30 days or have ever taken part in a study of any type of inhaled insulin. * you have a history of asthma or allergies. * you have a chronic cough. * you have had a kidney transplant, are on dialysis, or have poor kidney function. * you have a history of chest pain, heart attack, or you have a heart condition that limits your physical activity due to discomfort.
safety and tolerability of a prostaglandin ocular implant for treatment of open angle glaucoma

Conditions: Open-angle Glaucoma

Summary: a single centre, open label, study to assess the safety, tolerability and biodegradation of pa5108 ocular implant in adults who have open angle glaucoma (primary or secondary).

participants who are currently managing their open angle glaucoma with combination drop therapy will be recruited. drop therapy will cease in the treatment eye and continue in the contralateral eye. the treated eye will receive via injection, a single pa5108 ocular implant. participants will be monitored for safety and tolerability of the ocular implant until it completely biodegrades.

Eligibility criteria:
inclusion criteria: * grade 3 or 4 open angle glaucoma (shaffer-etienne scale) * visual acuity in non-study eye same or better than study eye * currently taking topical ocular hypotensive medication including a prostaglandin analogue exclusion criteria: * aphakic eyes * only one eye * history of, or current uveitis, cystoid macular edema (cme) or cornea edema * intraocular surgery or cornea/refractive surgery in study eye in past 6 months or anticipate need for eye surgery (including laser) in study eye during study period * current retinal detachment * uncontrolled infection in the eye
the vascular effects of exenatide versus metformin in patients with pre-diabetes

Conditions: Impaired Glucose Tolerance

Summary: the purpose of this study is to compare the effects of exenatide versus metformin on vascular health with chronic (3-month) therapy and during a 2-hour period following a meal in patients with pre-diabetes. it is predicted that exenatide will improve vascular health to a greater degree compared to metformin.


Eligibility criteria:
inclusion criteria: * greater than or equal to 18 years old * impaired glucose tolerance: 2-hr oral glucose tolerance test (ogtt) plasma glucose \>140 mg/dl or impaired fasting glucose: fasting glucose \> or = 100 mg/dl or elevated glycosylated hemoglobin: hemoglobin a1c \> or = 5.7% * abdominal obesity: waist circumference \>102 cm (men) and \>88 cm (women) * stable cardiovascular medication regimen (or other medications known to affect endothelial function) at least 1 month prior to enrollment and throughout the study exclusion criteria: * type 2 diabetes * current use of glycemic control medications within one month of randomization * fasting glucose \>126 mg/dl * current use of weight loss medication * previous weight loss surgery * history of severe gastrointestinal disease * standard clinical contraindications to exenatide or metformin therapy * unstable angina * heart failure * stroke or coronary artery bypass graft within 3 months of screening * women who are currently pregnant or planning to become pregnant * breastfeeding women * clinically significant liver disease * creatinine \> 1.5 mg/dl * hepatic function greater than 3 times upper limit of normal * patients who are mentally incompetent and cannot sign a patient informed consent
a real world study about pmn

Conditions: Primary Membranous Nephropathy

Summary: we designed a randomized, controlled, multicenter clinical study to compare the efficacy and safety of rituximab combined with hormones versus rituximab monotherapy in the treatment of primary membranous nephropathy. at the same time, we conducted a real-world study on patients who did not meet the inclusion and exclusion criteria or were unwilling to enter the rct cohort, to further observe the trial results in a broader population.

outcomes * primary objective treatment of primary membranous nephropathy with conventional clinical protocols and observation of its effectiveness and safety in a wide population. * exploratory purpose 1. evaluate the genome-wide changes in kidney and peripheral blood during treatment. 2. to evaluate the changes in the single-cell transcriptome of the kidney and peripheral blood during treatment. 3. evaluate the changes in the rna transcriptome of the kidney and peripheral blood during treatment. 4. evaluate the changes in the renal and peripheral blood proteome during treatment. 5. assess the changes in the metabolome during treatment. 6. assess changes in the microbiome during treatment. 7. predict the effective population of rituximab by baseline renal pathological images. * primary outcome the complete response rate at 12 months; * secondary outcomes 1. response rates at 6, 12, 18 and 24 months (including the proportion of participants with complete response and partial response); 2. median remission time; 3. proportion of patients without recurrence at 12, 18 and 24 months; 4. median non-recurrence time; 5. cumulative dose of glucocorticoids; 6. cd19+ cell count, anti-pla2r antibody expression level; 7. renal function index: egfr; 8. incidence of adverse events;

Eligibility criteria:
inclusion criteria: 1.men and women aged over 18 years; 2.patients diagnosed as primary membranous nephropathy (pmn) by renal biopsy; 3.after treatment with ace inhibitors or arbs for at least 3 months, those who have an average 24-hour urine protein ≥ 3.5g twice a week. - exclusion criteria: 1. patients with secondary membranous nephropathy (such as hepatitis b and c, systemic lupus erythematosus, drug therapy, malignant tumors and other secondary causes; 2. active infection, such as active hepatitis b or hepatitis c, tuberculosis (evidence of active tuberculosis infection within 1 year), or human immunodeficiency virus hiv infection (positive for anti-hiv antibodies), etc. 3. a history of immunodeficiency, including other acquired or congenital immunodeficiency diseases, or organ transplantation. -

Keywords: real-world study
effect of electromagnetic stimulation combined with visceral manipulation on stress urinary incontinence in postmenopausal women

Conditions: Stress Urinary Incontinence; Postmenopausal Disorder

Summary: to examine the effect of electromagnetic stimulation combined with visceral manipulation on stress urinary incontinence in postmenopausal women

according to the authors' knowledge, no prior studies that included ms with a vmt maneuvers to improve the success rates of stress urinary incontinence (sui) treatment. consequently, the purpose of this study was to assess the effect of electromagnetic field stimulation with vmt and pfmt in treatment of postmenopausal women with sui.

Eligibility criteria:
inclusion criteria: fifty postmenopausal women suffering from sui with grades mild to moderate, were referred from........hospital after sui diagnosis confirmation with urodynamics. they were selected from outpatient clinic of department of physical therapy for women's health of the faculty of physical therapy, cairo university. the inclusion criteria included sedentary and medically stable postmenopausal women, with age range of 50 to 66 years old. exclusion criteria: resence of a urinary tract infection (uti), other types of ui, previous incontinence and pelvic floor surgeries, metallic implant, contraindications for ms, cognitive alterations, collagen or muscle-related diseases, and neurological abnormalities were exclusion criteria.
total hip arthroplasty using small direct anterior incision: the role of short femoral stem

Conditions: Total Hip Arthroplasty

Summary: this study aims to investigate short-term outcomes following the use of two femoral stems used during total hip arthoplasty: the fitmore femoral stem and the m/l taper femoral stem.


Eligibility criteria:
inclusion criteria: * patient signed an irb, study specific informed patient consent. * patient is a male or non-pregnant female age 18 years or older at the time of study device implantation. * patient has primary diagnosis of non-inflammatory degenerative joint disease. * patient is a candidate for primary cementless total hip replacement. * patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation. exclusion criteria: * patient has a body mass index (bmi) \> 40 kg/m2. * patient has an active or suspected infection at the time of device implantation. * patient is immunologically suppressed. * patient requires revision surgery of a previously implanted total hip replacement. * patient has a known sensitivity to device materials.
a non-interventional retrospective study on overall survival in completely resected chinese nsclc patients with adenocarcinoma histology- ican extension study

Conditions: Overall Survival

Summary: ican was a non-interventional study to explore the egfr gene mutation status, clinical outcome and recurrent risk factors in early stage chinese nsclc with adenocarcinoma histology after complete resection (nis-ocn-dum-2009/1). the study had enrolled 571 patients from apr. 2010 to dec. 2010 in 24 sites located in the mainland of china. the study had completed and major results showed that egfr mutation rate was 55.1% and 3-year dfs rate was 61.7% in early stage chinese nsclc with adenocarcinoma histology after complete resection. postoperative pathologic stage, gender, surgical and resection types had a statistically significant association with 3-year dfs. this study is ican extension study with the purpose to collect the overall survival data from previous ican study. approximately 571 patients who participated in ican study will be enrolled.

primary objective * to observe the overall survival of early stage nsclc with adenocarcinoma histology after complete resection that had enrolled in i can study. secondary objectives * to observe the updated dfs of early stage nsclc with adenocarcinoma histology after complete resection that had enrolled in i can study; * to observe the treatment pattern after tumor recurrence of early stage nsclc with adenocarcinoma histology after complete resection that had enrolled in i can study in real-world setting; * to explore the risk factors of os for early stage nsclc with adenocarcinoma histology after complete resection that had enrolled in i can study in real-world setting, such as egfr mutation status, gender, smoking history, treatment pattern after recurrence, etc.

Eligibility criteria:
inclusion criteria: 1. patients ≥18 years old. 2. provision of informed consent prior to any study specific procedures 3. histological diagnosed as adenocarcinoma type of non-small cell lung cancer 4. have completed lung cancer operation 5. the tumour egfr gene mutation status test was performed as regular medical practice exclusion criteria: 1. no provision of informed consent or ec approve informed consent waiver prior to any study specific procedures; 2. patients withdrew consent for ican study; 3. patients in whose medical record was objected to use the existing data for scientific research
german registry for transcatheter tricuspid valve interventions

Conditions: Tricuspid Regurgitation; Tricuspid Valve Insufficiency; Heart Valve

Summary: multicentre observational study of patients with severe tricuspid regurgitation and interventional treatment.

severe tricuspid regurgitation occurs in around 1.5 % of men and 5.6 % of women and it is associated with significant morbidity and mortality. current guidelines recommend cardiac surgery, especially in those patients who are undergoing left side valve surgery. nevertheless many patients are not eligible for surgical tricuspid valve repair due to an high risk of mortality. therefore interventional devices for treatment of tricuspid regurgitation have been established to offer these patients an alternative treatment option. the aim of this study is to analyse the success and saftey aspects of different interventional repair techniques for severe tricuspid regurgitation. therefore in this prospectively designed observational study clinical, echocardiographic and laboratory parameters will be collected.

Eligibility criteria:
inclusion criteria: * interventional treatment of severe tricuspid regurgitation (isolated or in combination with another interventional treatment) with a ce certified product for tricuspid valve repair * informed consent corresponding to criteria of good clinical practice and the decleration of helsinki as well as to standards of the local ethic commission. exclusion criteria: * no agreement to participation * age \< 18 years

Keywords: tricuspid regurgiation tricuspid valve insufficiency interventional treatment heart valve diseases
mixed reality gaming for chronic low back pain

Conditions: Recurrent Low Back Pain

Summary: mixed reality gaming for chronic low back pain

the company, from the future and university of alabama at birmingham (uab) team aimed to develop a virtual reality (vr) game that integrated with the features of a specialized self-driven treadmill to provide accessible and progressive walking challenges for individuals with chronic low back pain (lbp). the game was designed to go beyond typical vr research efforts and provide a truly immersive and engaging experience that would motivate individuals with high pain-related fear to keep moving.

Eligibility criteria:
inclusion criteria: history of chronic low back pain exclusion criteria: no major neurological, cardiac, pulmonary, or other orthopedic injuries

Keywords: walking exercise exergaming
thuflep/solep : initial experience and results of prostate laser enucleation with thulium-fiber laser (tfl)

Conditions: Prostate Hyperplasia

Summary: thuflep tlf: initial experience and results of prostate laser enucleation with fibrous thulium laser (tlf)

while prostate laser enucleation is being confirmed as the new gold standard for surgical management of benign prostate hypertrophy, the holmium:yag laser is currently the most widely used. a new laser technology, the fibrous thulium laser (tfl), has recently appeared with clearly superior results for lithotripsy. the question therefore arises of the surgical and functional results of the use of fibrous thulium for prostate enucleation.

Eligibility criteria:
inclusion criteria: * patients superior or equal to 18 years old * benign prostate hypertrophy ( more than 30cc.) * indication to surgical treatment * no contraindication for surgery * no opposition to participating in the study exclusion criteria: * evidence of urethral stenosis * evidence of a bladder tumour * evidence of prostate cancer known or confirmed by prostate biopsies if suspected * known neurological bladder * refusal to participate
the effect of helminth infection plus covid-19 infection on the immune response and intestinal microorganisms

Conditions: COVID-19

Summary: this is a pilot, cross-sectional, sample collection study to characterize the immune response and intestinal microorganisms in people with and without covid-19 antibodies and helminth infection.

this is a pilot, cross-sectional, sample collection study to characterize the immune response and intestinal microbiota in people with and without sars-cov-1 antibodies and helminth infection. a target sample size of 1500 participants aged 5 years or older will undergo a one-time blood and stool collection for sars-cov-2 antibody testing, diagnosis of parasitic infections, and experimental studies including transcriptomics (rna) and microbiome (intestinal microorganisms) characterization. participants willing to take part in the study will be selected from households in the tiruvallur district, tamil nadu, india. individual study participation involves a single study visit. participants will be informed of the results of clinical testing and will be referred for medical care as appropriate.

Eligibility criteria:
inclusion criteria: * able to provide informed consent. exclusion criteria: * poor venous access precluding venipuncture. * history of any illness or condition which, in the investigator's judgment, may substantially increase the risk associated with the participant's participation in the protocol, or compromise the scientific objectives. participants may be co-enrolled in other studies; however study staff should be notified of co-enrollment.
radio/pathological evaluation of tongue cancer infiltration

Conditions: Oral Squamous; Cell Carcinoma

Summary: the aim of the study is to assess the good correlation and prediction of the doi for the post-operative pathological results and prognosis.


Eligibility criteria:
inclusion criteria: * patients chirurgically treated for an oscc * t1 t2 t3 * ct scanner in their medical file exclusion criteria: * t4 * r+ résection * artefacts on ct scanner

Keywords: doi infiltration oral cavity cancer oscc tongue cancer ct scanner